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Induced apoptosis of neuroblastoma by treatment with anti-oncogene peptide 
nucleic acids 
 
Neuroblastoma is a cancerous tumor found in the nervous system of young children. These 
cells overexpress bcl-2 and FLIP proteins, which both prevent apoptosis. The bcl-2 protein 
inhibits the pro-apoptotic protein bax, and the FLIP protein inhibits caspase-8, an enzyme 
that mediates apoptosis. Antisense PNAs, or peptide nucleic acids, which are similar to DNA 
molecules, may have potential to induce apoptosis in these cells, by inhibiting bcl-2 and FLIP 
gene expression. The objective of this study was to determine whether these neuroblastoma 
cells could be induced to undergo apoptosis when treated with anti-oncogene PNAs. The 
effect of anti-bcl-2 and anti-FLIP PNAs on IMR-32 and SH-SY5Y neuroblastoma cells was 
tested. The cells were treated with each of the PNAs separately, a combination of the two, 
and with nonsense PNA as a negative control. Using Western blots, the protein expression 
after treatment was analyzed. Then the anti-Fas antibody CH11 was added, and the cells’ 
ability to undergo apoptosis was analyzed by TUNEL assays and nucleosome ELISA. It was 
found that anti-bcl-2 PNA, in IMR-32 cells only, resulted in decreased protein expression and 
in apoptosis through the Fas receptor pathway. Failure of anti-FLIP PNA to induce apoptosis 
suggested that the anti-bcl-2 PNA acted by a caspase-8-independent mechanism, perhaps 
involving protein kinase C, MAPK, the Traf/TRAIL system, or other mitochondrial pathways. 
Because the Fas receptor mediates drug-induced apoptosis, treatment with anti-oncogene 
PNAs may cause resistant neuroblastoma cells to become susceptible to apoptosis during 
chemotherapy. 
